TRV250: a novel biased ligand at the delta receptor for the potential treatment of migraine
TRV734, a G Protein-biased Ligand of the µ-opioid Receptor, Demonstrates Oral Bioavailability, Displays Predictable Pharmacokinetics and Pharmacodynamics, and Provides Analgesia in Healthy Adults
Formulation and Food Effect Studies of TRV734, an Oral, G Protein-biased Ligand of the µ-opioid Receptor
Biased ligands: pathway validation for novel GPCR therapeutics. Current Opinions in Pharmacology 2014 16: 108-115.
This poster introduces TRV734, a G protein-biased mu-opioid receptor ligand that is analgesic with improved gastrointestinal effects compared to morphine and oxycodone in rodents. TRV734 displays promising pharmacokinetics in non-human primates; together these data suggest that oral TRV734 may deliver powerful analgesia with better tolerability than currently used oral opioids for acute and chronic pain.
Nat Rev Drug Discov. 2013 Mar;12(3):205-16
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93
AHA Journals Free Article
Science. 2013 Mar 21 (online)
Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol. 2011 Sep. PubMed Central PMCID: PMC3164332
β-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci. 2007 Aug
β-arrestins and cell signaling. Annu Rev Physiol. 2007
Copyright © Trevena, Inc.